HEMATOLOGY

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination with azacitidine and venetoclax in AML.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

Solly Chedid, MD, shares insights on optimizing anemia management in patients with lower-risk MDS and outlines remaining unmet needs in treating anemia.

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.

A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.

Mikkael A. Sekeres MD, MS, discusses transfusion independence rates with imetelstat in patients with low- to intermediate-1 risk myelodysplastic syndromes.

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

Acalabrutinib plus bendamustine and rituximab led to a 27% reduction in the risk of disease progression or death in the frontline setting for older patients with mantle cell lymphoma.

During a Case-Based Roundtable® event, Amy DeZern, MD, MHS, discussed dosing approaches for managing anemia with luspatercept in patients with low-risk myelodysplastic syndrome.

Following voluntary withdrawal in 2014, denileukin diftitox is now available again for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

The FDA has rejected the SIERRA study data for Iomab-B’s biologics license application filing due to insufficient evidence of overall survival improvement.

The FDA has granted an orphan drug designation to alemtuzumab, a chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.

Harry Erba, MD, PhD, provided his insights into the groundbreaking myeloMATCH trial and its influence on the treatment of acute myeloid leukemia and myelodysplastic syndromes.

The investigational new drug application for UB-VV111, potentially the first in situ generated CD19 CAR T-cell therapy, has been cleared by the FDA, and a phase 1 trial in hematologic malignancies will begin.

The FDA has extended the PDUFA target action date for the new drug application of revumenib for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia to December 26, 2024.

The NCCN has updated its guidelines to recommend imetelstat as a top treatment for symptomatic anemia in lower-risk MDS, following its FDA approval based on encouraging phase 3 trial results.

Guillermo Garcia-Manero, MD, provides advice to community oncologists on the treatment of anemia for patients with lower-risk MDS.

An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.

A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.

Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.

Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.

A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.

Guillermo Garcia-Manero, MD, reviews recent results from the COMMANDS study investigating luspatercept versus epoetin alfa in patients with ESA-naïve, transfusion dependent LR-MDS.

An expert on the treatment of lower-risk MDS outlines practices for identifying patients who are suitable to receive erythroid maturating agents for treatment of anemia.

A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.